Rebecca focuses on European prosecution, opposition and appeal work in the life sciences sector. She has secured allowance for a number of European applications relating to antibody products in clinical trials and has a strong track record of success in both defensive and offensive opposition proceedings.
Areas of Expertise
- Therapeutic biomolecules
- Antibodies, including novel antibody formats and engineering
- Sequence technologies
- Diagnostics, including liquid biopsy
Rebecca’s clients include multinational healthcare and biotechnology companies, as well as US and European life science companies of all sizes and US law firms.
Rebecca has a degree in Biological Sciences from Oxford University, where she won the Gill Prize for the student with the highest mark in her year.
She joined Mewburn Ellis LLP in 2000, qualifying as both a Chartered Patent Attorney and a European Patent Attorney in 2004 and joining the partnership in 2008.
Recognised in The Legal 500 (2016) as “highly active on the life sciences side”.
Client feedback: “a talented patent attorney,” who “crafted clear and persuasive legal arguments” and “appreciated the technical aspects of our case” - Multinational Biotech Company.